<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="36280961-78ee-bfb3-e063-6294a90a6cb3"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Betamethasone Valerate
 <br/>
Cream USP, 0.1%
</title>
   <effectiveTime value="20250527"/>
   <setId root="3c85be0f-2731-44f1-a18e-d3852d54846f"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="146974886"/>
            <name>Sun Pharmaceutical Industries, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="243339023"/>
                        <name>Sun Pharma Canada Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51672-1269" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="36288b44-dcce-2f00-e063-6394a90a7140"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250527"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="51672-1269" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>BETAMETHASONE VALERATE</name>
                        <formCode code="C28944" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CREAM"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Betamethasone Valerate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T5L8T28FGP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MINERAL OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4T6H12BN9U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PETROLATUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U076Q6Q621" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 1000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="867H4YOZ8Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CETEARETH-15</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="936JST6JCN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CETYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2KR89I4H1Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="E4GA8884NN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHOSPHORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36W53O7109" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CHLOROCRESOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9IFA5XM7R2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BETAMETHASONE VALERATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9842X06Q6M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BETAMETHASONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="51672-1269-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="19880106"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="45" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="51672-1269-6" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="19880106"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA072041" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19880106"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="36280961-78ef-bfb3-e063-6294a90a6cb3"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20170418"/>
            </section>
         </component>
         <component>
            <section>
               <id root="36280961-78f0-bfb3-e063-6294a90a6cb3"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Betamethasone Valerate Cream USP, 0.1% contains betamethasone valerate USP, a synthetic adrenocorticosteroid for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.</paragraph>
                  <paragraph>Betamethasone valerate is a white to practically white odorless crystalline powder practically insoluble in water, freely soluble in acetone and chloroform, soluble in alcohol, and slightly soluble in benzene and ether. Chemically it is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1, 4-diene-3,20-dione 17-valerate. The structural formula is:</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="35%" align="right" valign="top"/>
                     <col width="30%" align="center" valign="top"/>
                     <col width="35%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td colspan="3" align="center">
                              <renderMultiMedia referencedObject="MM1"/>
                           </td>
                        </tr>
                        <tr>
                           <td>Molecular Formula: C
    
     <sub>27</sub>H
    
     <sub>37</sub>FO
    
     <sub>6</sub>
                           </td>
                           <td/>
                           <td>Molecular Weight: 476.59</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Each gram of Betamethasone Valerate Cream USP, 0.1% contains 1.2 mg betamethasone valerate (equivalent to 1 mg betamethasone) in a soft, white, hydrophilic cream of ceteareth-15, cetyl alcohol, mineral oil, polyethylene glycol 1000, propylene glycol, purified water, stearyl alcohol, white petrolatum, phosphoric acid and sodium hydroxide (for pH adjustment); chlorocresol is present as a preservative.</paragraph>
               </text>
               <effectiveTime value="20170418"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="betamethasone-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="36280961-78f1-bfb3-e063-6294a90a6cb3"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.</paragraph>
                  <paragraph>The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.</paragraph>
               </text>
               <effectiveTime value="20170418"/>
               <component>
                  <section>
                     <id root="36280961-78f2-bfb3-e063-6294a90a6cb3"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics</title>
                     <text>
                        <paragraph>The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.</paragraph>
                        <paragraph>Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.</paragraph>
                        <paragraph>Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.</paragraph>
                     </text>
                     <effectiveTime value="20170418"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="36280961-78f3-bfb3-e063-6294a90a6cb3"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.</paragraph>
               </text>
               <effectiveTime value="20170418"/>
            </section>
         </component>
         <component>
            <section>
               <id root="36280961-78f4-bfb3-e063-6294a90a6cb3"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.</paragraph>
               </text>
               <effectiveTime value="20170418"/>
            </section>
         </component>
         <component>
            <section ID="Precautions">
               <id root="36280961-78f5-bfb3-e063-6294a90a6cb3"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20170418"/>
               <component>
                  <section>
                     <id root="36280961-78f6-bfb3-e063-6294a90a6cb3"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.</paragraph>
                        <paragraph>Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.</paragraph>
                        <paragraph>Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.</paragraph>
                        <paragraph>Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.</paragraph>
                        <paragraph>Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see
 
  <content styleCode="bold">
                              <linkHtml href="#PrePediatric">PRECAUTIONS-Pediatric Use</linkHtml>
                           </content>).

 </paragraph>
                        <paragraph>If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.</paragraph>
                        <paragraph>In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.</paragraph>
                     </text>
                     <effectiveTime value="20170418"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="36280961-78f7-bfb3-e063-6294a90a6cb3"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information For Patients</title>
                     <text>
                        <paragraph>Patients using topical corticosteroids should receive the following information and instructions:</paragraph>
                        <list listType="ordered">
                           <item>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.</item>
                           <item>Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.</item>
                           <item>The treated skin should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.</item>
                           <item>Patients should report any signs of local adverse reactions especially under occlusive dressing.</item>
                           <item>Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.</item>
                        </list>
                     </text>
                     <effectiveTime value="20170418"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="36280961-78f8-bfb3-e063-6294a90a6cb3"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory tests</title>
                     <text>
                        <paragraph>The following tests may be helpful in evaluating the HPA axis suppression:</paragraph>
                        <list listType="unordered">
                           <item>Urinary free cortisol test</item>
                           <item>ACTH stimulation test</item>
                        </list>
                     </text>
                     <effectiveTime value="20170418"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="36280961-78f9-bfb3-e063-6294a90a6cb3"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, and Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.</paragraph>
                        <paragraph>Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.</paragraph>
                     </text>
                     <effectiveTime value="20170418"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="36280961-78fa-bfb3-e063-6294a90a6cb3"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20170418"/>
                     <component>
                        <section>
                           <id root="36280961-78fb-bfb3-e063-6294a90a6cb3"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>Teratogenic Effects</title>
                           <effectiveTime value="20170418"/>
                           <component>
                              <section>
                                 <id root="36280961-78fc-bfb3-e063-6294a90a6cb3"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Pregnancy Category C</title>
                                 <text>
                                    <paragraph>Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.</paragraph>
                                 </text>
                                 <effectiveTime value="20170418"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="36280961-78fd-bfb3-e063-6294a90a6cb3"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities
 
  <content styleCode="italics">not</content>likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

 </paragraph>
                     </text>
                     <effectiveTime value="20170418"/>
                  </section>
               </component>
               <component>
                  <section ID="PrePediatric">
                     <id root="36280961-78fe-bfb3-e063-6294a90a6cb3"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.</content>
                        </paragraph>
                        <paragraph>Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.</paragraph>
                        <paragraph>Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.</paragraph>
                     </text>
                     <effectiveTime value="20170418"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="36280961-78ff-bfb3-e063-6294a90a6cb3"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.</paragraph>
               </text>
               <effectiveTime value="20170418"/>
            </section>
         </component>
         <component>
            <section>
               <id root="36280961-7900-bfb3-e063-6294a90a6cb3"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see
 
  <content styleCode="bold">
                        <linkHtml href="#Precautions">PRECAUTIONS</linkHtml>
                     </content>).

 </paragraph>
               </text>
               <effectiveTime value="20170418"/>
            </section>
         </component>
         <component>
            <section ID="DA">
               <id root="36280961-7901-bfb3-e063-6294a90a6cb3"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Apply a thin film of Betamethasone Valerate Cream USP, 0.1% to the affected skin areas one to three times a day. Dosage once or twice a day is often effective.</paragraph>
               </text>
               <effectiveTime value="20170418"/>
            </section>
         </component>
         <component>
            <section>
               <id root="36280961-7902-bfb3-e063-6294a90a6cb3"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Betamethasone Valerate Cream USP, 0.1% is supplied in 15 gram (NDC 51672-1269-1) and 45 gram (NDC 51672-1269-6) tubes.</paragraph>
               </text>
               <effectiveTime value="20170418"/>
               <component>
                  <section>
                     <id root="36280961-7903-bfb3-e063-6294a90a6cb3"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Store at 20° to 25°C (68° to 77°F)</content>[see USP Controlled Room Temperature].

 </paragraph>
                     </text>
                     <effectiveTime value="20170418"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="36280961-7904-bfb3-e063-6294a90a6cb3"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1 
  <br/>  Dist. by:
 
  <content styleCode="bold">Taro Pharmaceuticals U.S.A., Inc.,</content>Hawthorne, NY 10532

 </paragraph>
                  <paragraph>Revised: February, 2015 
  <br/>  PK-0759-6 
  <br/>  372
 </paragraph>
               </text>
               <effectiveTime value="20170418"/>
            </section>
         </component>
         <component>
            <section>
               <id root="36280961-7905-bfb3-e063-6294a90a6cb3"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 15 g Tube Carton</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 51672-1269-1</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">15 g</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Betamethasone Valerate 
   <br/>  Cream USP, 0.1%
  </content>
                  </paragraph>
                  <paragraph>FOR EXTERNAL USE ONLY. 
  <br/>  NOT FOR OPHTHALMIC USE.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep this and all medications out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">TARO</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20170418"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 15 g Tube Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="betamethasone-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>